BURGESS HILL, England, September 1
With some 20,000 UK children with Type 1 diabetes(i) about to start thenew school year, new guidance from the National Institute for Health andClinical Excellence (NICE) looks set to revolutionise the way children managetheir diabetes, granting more freedom and control for their condition, bygreater access to insulin pump therapy. The new recommendations finallyacknowledge key research(ii) supported by Roche, that shows the positiveimpact of pumps on quality of life for sufferers and their families.
Roche, a world leader in diabetes care and management services, has beenworking closely with diabetes healthcare specialists to raise awareness ofpump therapy and encourage and support new users. Roche welcomes the newguidelines that recommend greater access to insulin pump therapy to manageType 1 diabetes, particularly amongst children and young people, with pumpsreplacing traditional insulin injections which have been shown to interruptthe school day(iii).
Dr Katharine Barnard PhD, School of Psychology at the University ofSouthampton, one of the UK's leading authorities into quality of life issuessurrounding insulin pumps in Type 1 diabetes, who has worked with Roche says:"There are significant psychosocial benefits associated with insulin pumptherapy, particularly improved quality of life. The new NICE guidelinesshould facilitate greater access to this therapy, which will only be goodnews for patients and their families. For children it should have a positiveimpact on both their school and home life."
Benefits of replacing injections with insulin pump therapy include fewerhypoglycaemic episodes, the opportunity to participate in sports withouthaving to plan ahead and the choice to eat a wider variety of food as thepump can be easily adjusted to supply the right amount of insulin each momentof the day.
Britain is lagging behind other major countries in terms of diabetesmanagement with less than 1% of Type 1 cases using an insulin pump in the UK,compared to many other countries such as US and Germany where 15-20% use apump(iv). With a five fold increase in the number of under fives diagnosedover the past 20 years(v), and 1 child in 1,000(vi) affected, access toinsulin pump therapy is essential for children to have the opportunity tolive as close to a normal a life as possible and feel less 'controlled' bytheir diabetes as Dr Barnard's adolescent study amongst pump users found.
Dr Barnard continued: "The new guidance should hopefully open up accessto children and their families and pumps are then provided according to need,choice and suitability."
Insulin pumps are not suitable for everyone and they need thoroughexplanation and training. People can find out more by visitinghttp://www.accu-chek.co.uk where they can experience the Accu-Chek Spiritonline simulator, the most advanced insulin pump from Roche which closelymimics the pancreas by delivering insulin every three minutes(vii).
Headquartered in Basel, Switzerland, Roche is one of the world's leadingresearch-focused healthcare groups in the fields of pharmaceuticals anddiagnostics. As the world's biggest biotech company and an innovator ofproducts and services for the early detection, prevention, diagnosis andtreatment of diseases, the Group contributes on a broad range of fronts toimproving people's health and quality of life. Roche is the world leader inin-vitro diagnostics and drugs for cancer and transplantation, and is amarket leader in virology. It is also active in other major therapeutic areassuch as autoimmune diseases, inflammatory and metabolic disorders anddiseases of the central nervous system. In 2007 sales by the PharmaceuticalsDivision totalled 36.8 billion Swiss francs, and sales by the DiagnosticsDivision totalled 9.3 billion Swiss francs. Roche Diabetes Care posted 2007sales o